ALZN today
$1.41-$0.14 (-9.03%)close Nov 6, 2026Trend
DailyDowntrend (confirmed)
4 hourExpanding
1 hourStrong Bearish
15 minBearish
5 minStrong Bullish
Daily trend turns up above $1.95
Key levels
Resistance$1.73
Resistance$1.48
Support$1.31
Support$1.10
Latest news & SEC filings
LegalAlzamend Neuro Regains Nasdaq Compliance
EarningsAlzamend Neuro Posts Wider-Than-Expected Q1 Loss of $0.68 Per Share
All ALZN news →About Alzamend Neuro
Alzamend Neuro develops drug candidates aimed at Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD. Its two programs are AL001, a lithium-based compound, and ALZN002, a vaccine approach intended to help the immune system fight Alzheimer's. The company is based in the United States and licenses its underlying technology from the University of South Florida Research Foundation.
Based on the company's 10-K filed Jul 22, 2026.
Nasdaq · Healthcare
Alzamend Neuro, Inc. (ALZN)
What Is the Price Target for ALZN?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is ALZN a Buy or Sell Right Now?
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ALZN.
Start Free Trial →Is ALZN Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B
Fair Value
$1.06
7
Moat Score
NONE
1/9
Piotroski Score
-57.2
Altman Z-Score
What Is Smart Money Doing with ALZN?
Insider Signal
NEUTRAL
1 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ALZN Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
76.77%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for ALZN
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ALZN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:58:30 | $1.41 | 1,000 | $$1K | SELL |
| 17:45:39 | $1.44 | 2,000 | $$3K | MIDPOINT |
| 15:48:48 | $1.44 | 1,300 | $$2K | MIDPOINT |
| 15:28:43 | $1.34 | 1,000 | $$1K | SELL |
| 15:00:29 | $1.48 | 3,000 | $$4K | MIDPOINT |
5 dark pool trades shown · $$12K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Alzamend Neuro, Inc. (ALZN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings intelligence, and a complete investment thesis with entry and exit recommendations.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ALZN — frequently asked questions
What is ALZN stock price today?
Alzamend Neuro, Inc. (ALZN) is at $1.41, down 9.03% (-$0.14) at the Nov 6, 2026 close.
Why is ALZN stock moving today?
Latest ALZN news — Sep 16, 2026: Alzamend Neuro Regains Nasdaq Compliance · Sep 10, 2026: Alzamend Neuro Posts Wider-Than-Expected Q1 Loss of $0.68 Per Share
What do analysts rate ALZN?
Analyst ratings for ALZN: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did ALZN beat earnings?
ALZN last reported on Sep 10, 2026: EPS -$0.68 vs -$0.56 expected — a miss of 21.4%.
What are ALZN support and resistance levels?
Support: $1.31, $1.10, $0.86. Resistance: $1.48, $1.73, $1.95.
What are insiders doing with ALZN?
Insider activity: NEUTRAL, 1 buys and 0 sells in the last 90 days.
What is the latest news on ALZN?
Sep 16, 2026: Alzamend Neuro Regains Nasdaq Compliance · Sep 10, 2026: Alzamend Neuro Posts Wider-Than-Expected Q1 Loss of $0.68 Per Share